DexCom, Inc. vs Alphabet Inc Class A — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while Alphabet Inc Class A trades at $355.87 (market cap $4.52T). The key difference: Alphabet Inc Class A is far larger — about 161.1× DexCom, Inc.'s market cap, and Alphabet Inc Class A pays a 0.24% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GOOGL | |
|---|---|---|
Market Cap | $28.06B | $4.52T |
Sector | Health | Media |
52-Week High | $89.53 | $402.62 |
52-Week Low | $54.84 | $182.97 |
Enterprise Value | $27.03B | $4.49T |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Alphabet (GOOGL) trades at $354.37, down 1.43% on the day, amid a bullish technical setup with strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Financial health is solid, with 2025 revenue of $402.84 billion and net income of $132.17 billion, reflecting a net margin of 32.8%. Positive news flow highlights AI-driven growth and strategic partnerships.
Outlook remains positive given earnings momentum, AI expansion, and a consensus price target of $431.78 implying 22% upside. Risks include antitrust scrutiny and tech sector volatility. Institutional sentiment is strongly bullish with 85% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →